Effects of opioid receptor agonists on cAMP second messenger system.
OBJECTIVE
To study the mechanism underlying the difference in physical dependence potential of morphine (Mor), methadone (Met), buprenorphine (Bup), etorphine (Eto), and dihydroetorphine (DHE).


METHODS
Adenylate cyclase of NG108-15 cells were used for studying the effects of different opiates on cAMP second messenger system.


RESULTS
Bup, DHE, and Eto were distinct from Mor in naloxone-precipitated rebound response of cAMP in NG108-15 cells chronically treated with these opiates. Naloxone given to NG108-15 cells treated with Mor for 24 h produced marked rebound response of adenylate cyclase. While no such rebound response was detected when the cells were treated with Bup, DHE, and Eto for 24 h. The naloxone-induced rebound response of cAMP in chronic Met-treated NG108-15 cells was also lower than that in chronic Mor-treated NG108-15 cells. Following a prolonged exposure to Bup, DHE, and Eto for 72 h, the naloxone-induced rebound response of cAMP in these cells was still markedly lower than that in Mor-treated cells. The substitution of Mor with Bup, Met, DHE, and Eto inhibited naloxone-induced rebound response of cAMP in chronic Mor-treated NG108-15 cells.


CONCLUSIONS
There were distinct differences among these opiates in regulating cAMP second messenger system, which was related to their physical dependence potential.
Liu
J G
JG
Institute of Pharmacology and Toxicology, Academy of Military Medical Sciences, Beijing, China. qinby@nic.bmi.ac.cn
Gong
Z H
ZH
Qin
B Y
BY
D000262:Adenylyl Cyclases / Q000378:metabolism; D000701:Analgesics, Opioid / Q000494:pharmacology; D002047:Buprenorphine / Q000494:pharmacology; D000242:Cyclic AMP / Q000378:metabolism*; D005048:Etorphine / Q000031:analogs & derivatives* / Q000494:pharmacology; D005910:Glioma / Q000473:pathology; D006801:Humans; D006822:Hybrid Cells; D008691:Methadone / Q000494:pharmacology; D009020:Morphine / Q000494:pharmacology*; D009447:Neuroblastoma / Q000473:pathology; D009293:Opioid-Related Disorders / Q000378:metabolism; D011957:Receptors, Opioid / Q000819:agonists*; D017465:Receptors, Opioid, delta / Q000819:agonists*; D014407:Tumor Cells, Cultured
D000701:Analgesics, Opioid; D011957:Receptors, Opioid; D017465:Receptors, Opioid, delta; D002047:Buprenorphine; D005048:Etorphine; D009020:Morphine; D000242:Cyclic AMP; D000262:Adenylyl Cyclases; C034765:18,19-dihydroetorphine; D008691:Methadone